Intersect ENT (XENT) Misses Q1 EPS by 10c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intersect ENT Reports First Quarter 2020 Results
May 11, 2020 7:01 AM EDTMENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (ENT) conditions, today reported financial results for the first quarter ended March 31, 2020.
First Quarter 2020 Overview
Revenue of $19.8 million in the first quarter of 2020, compared to $26.7 million in the first quarter of 2019 Cash, Cash Equivalents and Short-term Investments of $87.7 million as of March 31, 2020, compared to $90.6 million as of December 31, 2019.Total revenue was $19.8 million for the first quarter of 2020 compared to $26.7 million for the same... More
